Target Pipelines
In this product category, you will find reports in a tabular format providing you with the most uptodate competitive intelligence information about target-specific R&D pipelines. This low-cost product service provides information about active R&D projects for a given target in the format of Word tables.
They must then get down on their knees and beg the others to take pity on them. Doxycycline is an antibiotic drug used Khao Wong aprednislon 25 mg preis to treat a wide range of conditions. We have a total of 7500 tons of maize/corn/cowpea /soya /peanut.
Naltrexone is a very effective drug in the fight against opiate addiction, it works better than methadone. The problem, is that there needs to be enough time for the changes in dna (deoxyribonucleic viagra senza ricetta posologia snobbishly acid) to be made. In the united states, tamoxifen is a generic drug, and is manufactured by the company aventis.
Showing 1–20 of 51 results
- On the same day of purchaseThis product provides basic information on antibody therapy candidates in R&D targeting c-Met.€ 300.00
- On the same day of purchaseThis product provides basic information on approved therapeutics and therapy candidates in R&D targeting PSMA.€ 400.00
- On the same day of purchaseThis product provides basic information on immunotherapy candidates in research and development targeting mesothelin€ 300.00
- On the same day of purchaseThis product provides basic information on therapeutic antibodies in R&D targeting C-C chemokine receptor type 8 (CCR8).€ 300.00
- On the same day of purchaseThis product provides basic information on drug candidates in research and development targeting CD40 or CD40 ligand€ 300.00
- On the same day of purchaseThis product provides basic information on drug & imaging candidates in R&D targeting Fibroblast Activation Protein (FAP)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D targeting folate receptor alpha (FRα)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and immunotherapy candidates in R&D targeting IGF-1 or its receptor (IGF-1R)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Prolia & Xgeva (denosumab).€ 300.00
- July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Humira (adalimumab).€ 400.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Soliris (eculizumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Xolair (omalizumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Lucentis (ranibizumab)€ 300.00
- On the same day of purchaseThis product provides basic information on drug candidates in R&D as biosimilar antibodies of Eylea (aflibercept)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Stelara (ustekinumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D targeting thymic stromal lymphopoietin (TSLP) or its receptor (TSLP-R).€ 300.00
- February of 2023Antibody Target, Technology & Pipeline Database€ 1600.00
- July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
€ 2550.00€ 1800.00 - July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00